– SWITZERLAND, Basel – Versameb AG, transforming (m)RNA therapeutics to cure hard-to-treat and/or prevalent diseases, today announced the appointments of Hernán Levett, Dr. Lily Geidelberg (Ph.D.), Dr. Paul Korner (MD), and Dr. Alexandre LeBeaut (MD) to its Board of Directors.
“The experience of Hernán, Lily, Paul, and Alexandre significantly strengthens the board of directors as we advance our lead candidate, VMB-100, for the treatment of SUI, into clinical development and further expand our technology platform, Versagile, with the development of two discovery programs. Each of the new board members will add knowledge and expertise in all areas of the business as we ramp up for an exciting year of growth and development, executing our Company strategy through data readouts of our programs to deliver the promise of RNA therapeutics,” said CEO, Dr. Klaas Zuideveld.
About Hernán Levett
Hernán Levett has over 25 years of financial experience at international biotech and pharmaceutical companies in Europe and the US. Mr. Levett began his international pharma career at Novartis, where he held roles of increasing responsibility in various countries and for regional functions as well as being CFO for one of Novartis’ affiliates. Following a 10-year tenure at Novartis, Mr. Levett became VP of Finance at a US-listed company, InterMune, which was subsequently acquired by Roche for $8.3 billion. He then served as CFO at NASDAQ-listed company Auris Medical. He is currently CFO of Spexis AG (formerly Polyphor), a clinical-stage biopharmaceutical company.
He holds a CPA degree from the University of Buenos Aires, Faculty of Economics.
About Dr. Lily Geidelberg
Dr. Lily Geidelberg is a Senior Biotechnology Analyst at Brevan Howard, a leading global alternative investment management platform. Dr. Geidelberg is focused on compelling biopharma investment opportunities in the public markets and private biotech opportunities, combining domain expertise with macroeconomic analysis. She is also an independent board member of eureKING, the first European SPAC dedicated to bioproduction.
Dr. Geidelberg completed her Ph.D. at Imperial College London in mathematical modeling of infectious disease epidemics.
About Dr. Paul Korner
Dr. Paul Korner is a board-certified obstetrician & gynecologist physician executive with over 24 years of pharmaceutical and biotech industry experience, previously serving in senior R&D leadership positions for Ferring Pharmaceuticals, Ardelyx Inc., Sarepta Therapeutics, and Axovant Gene Therapies. He is currently the CMO of Agile Therapeutics. Dr. Korner has been responsible for multiple INDs/CTAs and more than 50 clinical trials (phases 1-4), leading to marketing authorization/approvals of 10 products. While serving as SVP of Clinical & Medical Affairs at Axovant Gene Therapies, he advanced two gene therapy programs into IND and BLA enabling clinical trials. He is a member of the scientific advisory team for Laidlaw Venture Partners and serves on the Board of Directors for Voltron Therapeutics.
About Dr Alexandre LeBeaut
Dr. Alexandre LeBeaut is a seasoned R&D executive who has worked with companies from the preclinical to the post-marketing stage and has extensive international drug development experience, particularly in immunology, oncology, gastroenterology, cardio-metabolic and infectious diseases. He has held leadership positions in global biopharmaceutical companies, including Schering-Plough Research Institute, Novartis, Sanofi, Axcan Pharmaceuticals, and Bluebird Bio. Most recently, Dr. LeBeaut served as EVP of R&D and CSO at Ipsen in the US and as CEO at the Institute for Advanced Clinical Trials for Children. He is a member of the Board of Calypso Biotech and OSE Immunotherapeutics.
Dr. LeBeaut earned his MD from Paris Diderot University and is board certified in Pediatrics from Paris Descartes University.
About Versameb
Versameb is reprogramming biology by developing enhanced mRNA therapeutics to cure hard-to-treat and prevalent diseases. We target the biology of complex diseases with optimally designed, separately patented, highly potent molecules with very low immunogenicity. Our VERSagile platform is versatile, scalable, and applicable to any nucleotide. Our ‘plug-and-play’ mRNA is targeted, both to specific tissues and cell compartments, and can up or down-modulate up to six proteins simultaneously – addressing the complex heterogeneity of most diseases, which have multiple inter-connected causes and targets. This genetic modulation stimulates the body to heal itself, making better and more cost-effective therapies accessible to the patients that need them. The initial focus in our rapidly growing candidate pipeline is VMB-100, a regenerative, multi-life-cycle therapy for stress urinary incontinence, with proof of concept in multiple animal models and human clinical studies due to start shortly. We also have two discovery programs for solid tumors targeting CTA/IND filing in 2026.
Source: www.versameb.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.